The low vascularization and the limited penetration of the radiopharmaceutical into the tumor microenvironment due to the high affinity of PSMA-ligands to the receptors, result in an overall low mean dose of radiation and a very low percentage of hypoxic tissue receiving the prescribed dose. This evidence concerns the gene FOLH1 and neoplasm.